BioCryst Pharmaceuticals

Founding and History

BioCryst was founded in 1986 as a University of Alabama at Birmingham–originated biotech. The company later became publicly traded and has since built an integrated organization spanning discovery, development, and commercialization, anchored by a portfolio in rare disease.

Therapy Areas and Focus

BioCryst focuses on rare and serious diseases, with core areas including:

• Hereditary angioedema (HAE)
• Complement-mediated diseases
• Infectious diseases (select programs and legacy assets)

Technology Platforms and Modalities

BioCryst is best known for structure-guided drug design and development of oral small-molecule therapeutics, alongside select protein therapeutics. The company’s R&D strategy includes targeting enzymatic pathways and immune system biology relevant to rare disease mechanisms.

Key Personnel

• Jon Stonehouse – President and Chief Executive Officer (with an announced CEO succession plan naming Charlie Gayer as next CEO)
• Charlie Gayer – President-designate / Chief Commercial Officer (CEO-designate)

Strategic Partnerships

BioCryst engages in partnerships across development, manufacturing, and commercialization as needed, and has historically worked with government, academic, and industry stakeholders to support infectious disease and rare disease programs. Its partnering activity is typically disclosed program-by-program.

FAQ Section

What is BioCryst’s core science and biotech platform?
BioCryst’s core platform is structure-guided discovery and development, with an emphasis on oral small molecules for rare diseases and other serious conditions.

What diseases and therapeutic areas does BioCryst focus on?
BioCryst primarily focuses on rare disease, including hereditary angioedema and complement-mediated disorders, with additional activity historically in infectious disease.

What programs and products are in BioCryst’s clinical pipeline?
BioCryst markets ORLADEYO (berotralstat) for prevention of HAE attacks and RAPIVAB (peramivir) for influenza. Its R&D pipeline includes clinical-stage programs in complement-mediated diseases and additional rare disease assets.

What is the latest company news and recent BioCryst events?
BioCryst’s recent activity has included lifecycle expansion for its HAE franchise and portfolio actions to strengthen its rare disease pipeline, alongside continued clinical development in complement-mediated disease.

What clinical trial data and results has BioCryst announced?
BioCryst has generated clinical evidence supporting ORLADEYO in HAE prophylaxis and has reported clinical and translational updates across its development portfolio. Detailed efficacy and safety readouts are typically communicated program-by-program.

What are BioCryst’s regulatory interactions and upcoming milestones?
BioCryst’s regulatory activities center on maintaining and expanding approvals for commercial products and advancing clinical-stage candidates through IND-enabling work and clinical development (Phases I–III, depending on the program).

Who comprises BioCryst’s leadership team and what is their track record?
The leadership team combines experience in rare disease commercialization, clinical development, and structure-based drug discovery. The company has progressed from a long-standing discovery organization into a commercial-stage rare disease company with marketed products and an active clinical pipeline.